ValuEngine upgraded shares of Calyxt (NASDAQ:CLXT) from a sell rating to a hold rating in a report published on Wednesday, March 14th.
A number of other research firms have also recently weighed in on CLXT. Zacks Investment Research upgraded shares of Calyxt from a sell rating to a hold rating in a research note on Tuesday, November 28th. Jefferies Group restated a buy rating and set a $27.00 target price on shares of Calyxt in a research note on Thursday, March 1st. Ladenburg Thalmann Financial Services started coverage on shares of Calyxt in a research note on Wednesday, December 20th. They set a buy rating and a $34.25 target price on the stock. Finally, Citigroup lowered their target price on shares of Calyxt from $27.00 to $22.00 and set a neutral rating on the stock in a research note on Thursday, November 16th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $29.05.
Calyxt (NASDAQ:CLXT) opened at $17.02 on Wednesday. Calyxt has a one year low of $9.26 and a one year high of $31.89. The company has a debt-to-equity ratio of 0.18, a quick ratio of 13.52 and a current ratio of 13.52.
In other Calyxt news, Director Alain Godard sold 19,825 shares of Calyxt stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $19.65, for a total value of $389,561.25. Following the sale, the director now directly owns 45,325 shares in the company, valued at approximately $890,636.25. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Bryan W.J. Corkal sold 19,600 shares of Calyxt stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $20.73, for a total transaction of $406,308.00. Following the completion of the sale, the chief financial officer now owns 92,300 shares in the company, valued at $1,913,379. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 104,496 shares of company stock worth $2,045,928.
Hedge funds and other institutional investors have recently made changes to their positions in the business. American International Group Inc. bought a new stake in Calyxt in the 3rd quarter valued at $133,000. California State Teachers Retirement System bought a new stake in Calyxt in the 3rd quarter valued at $323,000. Schwab Charles Investment Management Inc. bought a new stake in Calyxt in the 3rd quarter valued at $358,000. Goldman Sachs Group Inc. bought a new stake in Calyxt in the 4th quarter valued at $330,000. Finally, Deutsche Bank AG increased its holdings in Calyxt by 151.3% in the 4th quarter. Deutsche Bank AG now owns 18,378 shares of the company’s stock valued at $404,000 after acquiring an additional 11,064 shares during the last quarter. Institutional investors own 22.35% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Calyxt (NASDAQ:CLXT) Upgraded to Hold by ValuEngine” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/03/23/calyxt-clxt-rating-increased-to-hold-at-valuengine.html.
Calyxt Company Profile
Calyxt, Inc, a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for plants in the United States. It engages in the development of high oleic soybeans, high fiber wheat, herbicide tolerant wheat, powdery mildew resistant wheat, enhanced oil composition and herbicide tolerant canola, enhanced quality and herbicide tolerant alfalfa, late blight resistant potatoes, and cold storable/reduced browning potatoes, as well as enhanced protein composition, drought tolerant, herbicide tolerant, and enhanced yield soybeans.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Calyxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calyxt and related companies with MarketBeat.com's FREE daily email newsletter.